Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
about
Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysisSGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Sotagliflozin as a potential treatment for type 2 diabetes mellitus.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.SGLT2 inhibitors: are they safe?Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?Type 2 treatments for type 1 diabetes.Adjunctive therapy for glucose control in patients with type 1 diabetes.Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?Therapy of Type 1 Diabetes MellitusSGLT inhibitor adjunct therapy in type 1 diabetesMedications that cause weight gain and alternatives in Canada: a narrative review
P2860
Q33760535-04579FF6-F90B-414C-9282-ACCA1A6819EEQ36301818-8FF2736C-9499-489C-932E-BE0ABD7228DBQ38619164-61613074-7D4C-4940-AC4D-053E011E4C2AQ38628037-2F27BFA7-2A4A-4DE5-B739-438AFBC08F2DQ38658251-E60B0BC7-1E6F-42CF-A1F1-82F978509D0BQ38768667-91A675A4-1CD3-4446-B9D6-AD30A1AECDC5Q38821464-FFE052B9-6B4B-4705-AF9C-CE8F8A5D56BAQ38863649-300A9D8F-5A8B-4D08-8172-DA524DBFE5C2Q38906041-B450F8E4-4D7C-4D1A-A117-BE93E87D9A60Q39015250-80AD38A7-56ED-40BC-9991-6A81CB2DF1C7Q40266818-39E95B2A-C5F8-4770-AF78-48A6D3158C8FQ42008289-953F7C71-A862-4417-8767-40B1E88A5D17Q47291941-E25E9366-7C9B-4C6F-9770-92F450D50CEDQ47642298-5628E51B-02C2-4042-ADE2-499C0B3A71DFQ47722005-C2851EDC-5C6B-42C0-A0CD-07BCF8ABC5DEQ52562630-62E36167-8019-4D88-A5D1-DC6ADBD0E9F0Q53751922-5AC31C82-7B86-448D-BC6E-EC0CF6D518BDQ55234623-C3398B64-ED75-408F-B4A6-B5B8856C4EB2Q57157897-2B984283-6442-43C8-90AE-C77B46A19990Q57412611-A9E66833-B224-49C9-8128-FBFBB852532EQ58718282-442437ED-DA71-48A2-B9D8-BE066A9A8957Q58729864-94398323-AAF7-4FB1-9FE0-B8539A20614B
P2860
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Empagliflozin as adjunct to in ...... cebo-controlled trial (EASE-1)
@ast
Empagliflozin as adjunct to in ...... cebo-controlled trial (EASE-1)
@en
type
label
Empagliflozin as adjunct to in ...... cebo-controlled trial (EASE-1)
@ast
Empagliflozin as adjunct to in ...... cebo-controlled trial (EASE-1)
@en
prefLabel
Empagliflozin as adjunct to in ...... cebo-controlled trial (EASE-1)
@ast
Empagliflozin as adjunct to in ...... cebo-controlled trial (EASE-1)
@en
P2093
P2860
P921
P356
P1476
Empagliflozin as adjunct to in ...... cebo-controlled trial (EASE-1)
@en
P2093
H J Woerle
J Cescutti
J Eilbracht
N Soleymanlou
O E Johansen
T R Pieber
U C Broedl
P2860
P304
P356
10.1111/DOM.12494
P577
2015-06-17T00:00:00Z